
The Canadian study evaluated the real-world cost-effectiveness of the GLA: D® program versus usual care for hip and/or knee osteoarthritis (HKOA). Over 12 months, GLA: D® showed an adjusted incremental net monetary benefit (INMB) of $6,065 (MOH perspective). Lifetime models continued to favor GLA:D®, with over 50% probability of cost-effectiveness, highlighting its value in managing HKOA in real-world healthcare settings.
Like
Save
Share